Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Protalix BioTherapeutics, Inc. PLX

Set alert

Price alert · PLX

All alert types
2.61 USD +0.04 +1.76%

As of Nov 3, 10:37 AM ET

Bid
2.60 × 1,000
Ask
2.61 × 900
2.57 Day range 2.61
1.65 52-week range 3.19
YTD
+44.72%
1 year
+9.00%
Open
2.57
Prev close
2.56
Mkt cap
209.89M
Vol
29.80K
Avg vol
780.72K
EPS
0.23
P/E
11.33
Div yield
0.00%
More statistics
Low
2.57
High
2.61
Forward P/E
2.79
Beta
0.67
Short ratio
22.71
Inst. own
5.20%
Dividend
0.00
Ex-div date
50-d avg
1.43
200-d avg
1.21
1y target
14.00

3M chart

Chart tools
Interval
1m5m15m30m

Signals (12)
NameDateAgo
SMA: BearishOct 21, 20261 week ago
SMA: BullishOct 20, 20262 weeks ago
SMA: BearishOct 19, 20262 weeks ago
SMA: BearishOct 14, 20262 weeks ago
MACD: Sell SignalSep 25, 20261 month ago
MACD: Buy SignalAug 26, 20262 months ago
SMA: BullishAug 20, 20262 months ago
SMA: BearishAug 14, 20262 months ago
MACD: Sell SignalAug 14, 20262 months ago
SMA: BearishAug 13, 20262 months ago
MACD: Buy SignalAug 7, 20262 months ago
SMA: BullishAug 4, 20263 months ago

Financial health

Altman Z-Score

0.71 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

4 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

FMP rating

A-4 / 5 overall

  • DCF 1
  • Return on Equity 5
  • Return on Assets 5
  • Debt / Equity 3
  • P/E 3
  • P/B 3

Valuation

P/E -21.4×
FY 2016: -15.3×FY 2017: -1.0×FY 2018: -1.7×FY 2019: -2.7×FY 2020: -16.5×FY 2021: -1.3×FY 2022: -4.4×FY 2023: 14.8×FY 2024: 46.5×FY 2025: -21.4×
FY 2016 5y median -1.3× FY 2025
P/S 2.7×
FY 2016: 49.0×FY 2017: 4.1×FY 2018: 1.3×FY 2019: 0.9×FY 2020: 1.7×FY 2021: 1.0×FY 2022: 1.4×FY 2023: 1.8×FY 2024: 2.6×FY 2025: 2.7×
FY 2016 5y median 1.8× FY 2025
P/B 2.9×
FY 2016: -45.3×FY 2017: -2.8×FY 2018: -0.9×FY 2019: -0.7×FY 2020: -3.9×FY 2021: -6.1×FY 2022: -6.2×FY 2023: 3.6×FY 2024: 3.2×FY 2025: 2.9×
FY 2016 5y median 2.9× FY 2025
P/FCF -10.4×
FY 2016: -13.7×FY 2017: -7.9×FY 2018: -5.4×FY 2019: -2.4×FY 2020: -4.0×FY 2021: -3.1×FY 2022: -2.6×FY 2023: -48.7×FY 2024: 18.4×FY 2025: -10.4×
FY 2016 5y median -3.1× FY 2025
EV/EBITDA -45.7×
FY 2016: -20.2×FY 2017: -1.2×FY 2018: -3.3×FY 2019: -10.6×FY 2020: 34.1×FY 2021: -1.6×FY 2022: -7.7×FY 2023: 9.6×FY 2024: 18.7×FY 2025: -45.7×
FY 2016 5y median -1.6× FY 2025
EV/Sales 2.6×
FY 2016: 50.6×FY 2017: 4.2×FY 2018: 1.6×FY 2019: 1.7×FY 2020: 2.4×FY 2021: 0.8×FY 2022: 1.7×FY 2023: 1.9×FY 2024: 2.3×FY 2025: 2.6×
FY 2016 5y median 1.9× FY 2025
FCF Yield -9.6%
FY 2016: -7.3%FY 2017: -12.7%FY 2018: -18.4%FY 2019: -41.1%FY 2020: -25.3%FY 2021: -32.0%FY 2022: -38.6%FY 2023: -2.1%FY 2024: 5.4%FY 2025: -9.6%
FY 2016 5y median -9.6% FY 2025

Profitability

Gross Margin 47.8%
FY 2016: 8.7%FY 2017: 27.7%FY 2018: 72.8%FY 2019: 80.1%FY 2020: 82.7%FY 2021: 57.4%FY 2022: 58.9%FY 2023: 64.9%FY 2024: 54.5%FY 2025: 47.8%
FY 2016 5y median 57.4% FY 2025
Operating Margin -10.4%
FY 2016: -360.5%FY 2017: -163.8%FY 2018: -56.4%FY 2019: -19.6%FY 2020: 4.3%FY 2021: -53.4%FY 2022: -27.3%FY 2023: 16.0%FY 2024: 7.3%FY 2025: -10.4%
FY 2016 5y median -10.4% FY 2025
Net Margin -12.5%
FY 2016: -319.2%FY 2017: -395.9%FY 2018: -77.3%FY 2019: -33.4%FY 2020: -10.4%FY 2021: -71.9%FY 2022: -31.3%FY 2023: 12.7%FY 2024: 5.5%FY 2025: -12.5%
FY 2016 5y median -12.5% FY 2025
ROE -13.7%
FY 2016: 294.9%FY 2017: 266.6%FY 2018: 50.0%FY 2019: 26.0%FY 2020: 24.1%FY 2021: 457.0%FY 2022: 140.3%FY 2023: 24.8%FY 2024: 6.8%FY 2025: -13.7%
FY 2016 5y median 24.8% FY 2025
ROIC -9.6%
FY 2016: -47.4%FY 2017: -62.3%FY 2018: -54.0%FY 2019: -100.6%FY 2020: 6.5%FY 2021: -49.1%FY 2022: -53.2%FY 2023: 16.4%FY 2024: 5.6%FY 2025: -9.6%
FY 2016 5y median -9.6% FY 2025
ROA -8.0%
FY 2016: -35.7%FY 2017: -115.5%FY 2018: -43.3%FY 2019: -40.3%FY 2020: -9.6%FY 2021: -37.4%FY 2022: -26.8%FY 2023: 9.8%FY 2024: 4.0%FY 2025: -8.0%
FY 2016 5y median -8.0% FY 2025

Growth (YoY)

Revenue -1.2%
FY 2016: 110.8%FY 2017: 129.1%FY 2018: 62.4%FY 2019: 59.7%FY 2020: 15.0%FY 2021: -39.0%FY 2022: 24.2%FY 2023: 37.5%FY 2024: -18.5%FY 2025: -1.2%
FY 2016 FY 2025
Operating Income -240.4%
FY 2016: -40.1%FY 2017: -4.1%FY 2018: 44.1%FY 2019: 44.5%FY 2020: 125.3%FY 2021: -855.1%FY 2022: 36.4%FY 2023: 180.4%FY 2024: -62.6%FY 2025: -240.4%
FY 2016 FY 2025
EPS (diluted) -329.8%
FY 2016: -147.5%FY 2017: -2141.4%FY 2018: 72.3%FY 2019: 31.7%FY 2020: 82.1%FY 2021: -181.8%FY 2022: 50.0%FY 2023: 132.3%FY 2024: -63.4%FY 2025: -329.8%
FY 2016 FY 2025
Free Cash Flow -284.4%
FY 2016: -33.1%FY 2017: 66.7%FY 2018: 23.1%FY 2019: -137.1%FY 2020: -33.9%FY 2021: 56.1%FY 2022: -118.2%FY 2023: 90.4%FY 2024: 399.6%FY 2025: -284.4%
FY 2016 FY 2025

Financial Health

Current Ratio 2.5×
FY 2016: 1.1×FY 2017: 2.8×FY 2018: 2.1×FY 2019: 0.8×FY 2020: 0.6×FY 2021: 1.9×FY 2022: 1.4×FY 2023: 1.5×FY 2024: 2.3×FY 2025: 2.5×
FY 2016 5y median 1.9× FY 2025
Quick Ratio 1.5×
FY 2016: 1.0×FY 2017: 2.4×FY 2018: 1.8×FY 2019: 0.6×FY 2020: 0.5×FY 2021: 1.3×FY 2022: 0.9×FY 2023: 1.1×FY 2024: 1.5×FY 2025: 1.5×
FY 2016 5y median 1.3× FY 2025
Debt / Equity 0.2×
FY 2016: -7.8×FY 2017: -1.7×FY 2018: -0.9×FY 2019: -0.9×FY 2020: -2.4×FY 2021: -5.5×FY 2022: -3.1×FY 2023: 0.8×FY 2024: 0.1×FY 2025: 0.2×
FY 2016 5y median 0.1× FY 2025
Net Debt / EBITDA 2.2×
FY 2016: -0.6×FY 2017: -0.0×FY 2018: -0.6×FY 2019: -5.0×FY 2020: 10.4×FY 2021: 0.3×FY 2022: -1.5×FY 2023: 0.3×FY 2024: -2.2×FY 2025: 2.2×
FY 2016 5y median 0.3× FY 2025
Interest Coverage -4.6×
FY 2016: -7.9×FY 2017: -3.5×FY 2018: -2.5×FY 2019: -1.3×FY 2020: 0.3×FY 2021: -2.7×FY 2022: -5.1×FY 2023: 3.3×FY 2024: 3.7×FY 2025: -4.6×
FY 2016 5y median -2.7× FY 2025

Dividends

Dividend Yield 0.0%
FY 2016: 0.0%FY 2017: 0.0%FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016: 0.0%FY 2017: 0.0%FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2016 5y median 0.0% FY 2025

Annual · latest fiscal year ends 2025-12-31